Hydrated aluminum oxide, Magnesium hydroxide, Hydrated aluminum phosphate, Guar gum.
Tablet for oral suspension. It is a round, flat, beveled tablet, white-yellow in color, with a minty fragrance, and a diameter of 20 mm.
Each tablet contains: Active ingredients: Hydrated aluminum oxide 500 mg, Magnesium hydroxide 500 mg, Hydrated aluminum phosphate 300 mg, Guar gum 200 mg.
Excipients/Inactive Ingredients: Sodium cyclamate, sodium saccharin, magnesium stearate, mint flavor.
Pharmacotherapeutic Group: Antacids. ATC code: A02AD01.
Symptomatic treatment of pain linked to esophago-gastro-duodenal conditions.
Symptomatic treatment of gastroesophageal reflux.
Posology: Symptomatic treatment of pain linked to esophago-gastro-duodenal conditions: One tablet at the time of painful attacks without exceeding 4 doses per day.
Symptomatic treatment of gastroesophageal reflux: During an attack: 1 tablet after each of 3 meals and an additional one in case of pain for 4 to 6 weeks; As maintenance treatment: 1 tablet at the time of pain.
Method of administration: Dissolve one tablet in half a glass of water.
Dose of administration: Oral route.
Overdose: Large doses of aluminum can lead to an increased risk of phosphorus depletion, constipation even intestinal obstruction.
Patients with renal insufficiency may be at risk of hypermagnesemia.
Treatment: Actively monitor for timely treatment.
Related to magnesium: severe renal failure.
Hypersensitivity to any of the excipients of the drug.
In people with kidney failure and chronic dialysis patients, take into account the aluminum content (risk of encephalopathy).
This medicine contains less than 1 mmol (23 mg) sodium per tablet, i.e. it is essentially 'sodium-free'.
Effects on the ability to drive and use machines: The drug has no or negligible effect on the ability to drive and use machines.
There are no reliable data on teratogenesis in animals.
Clinically, there are currently no sufficiently relevant data to evaluate a possible malformative or fetotoxic effect of aluminum or magnesium hydroxides when administered during pregnancy.
Taking into account its low absorption, the use of this medication should only be considered during pregnancy if necessary.
Take into account the presence of aluminum and magnesium ions likely to impact transit: aluminum salts cause constipation, which can be added to the classic constipation of pregnancy; magnesium salts can cause diarrhea.
Try to limit the daily dose and, if possible, the duration of taking this medication.
Transit disorders (diarrhea and constipation).
Related to aluminum: phosphorus depletion in case of prolonged use or high doses.
Any adverse drug reactions should be immediately reported to the physician.
Drug interactions: Associations subject to precautions for use: Take antacids away from other medications administered orally (more than 2 hours if possible).
Calcium polystyrene sulfonate or sodium polystyrene sulfonate: Risk of metabolic alkalosis in people with renal insufficiency.
Citrates: Risk of facilitating the systemic passage of aluminum, particularly in cases of impaired renal function.
Others: Risk of reduced digestive absorption of the following medications taken orally: acetylsalicylic acid, alendronic acid, clodronic acid, etidronic acid, ibandronic acid, oxidronic acid, pamidronic acid, risedronic acid, tiludronic acid, zoledronic acid, alimemazine, atenolol, betamethasone, bictegravir, budesonide, chloroquine, chlorpromazine, chlortetracycline, ciprofloxacin, clindamycin, cortisone, cyamemazine, demeclocycline, dexamethasone, digoxin, dolutegravir, doxycycline, elvitegravir, enoxacin, ethambutol, famotidine, iron, fexofenadine, fluorine, fluphenazine, isoniazid, lansoprazole, ledipasvir, levofloxacin, levomepromazine, levothyroxine, liothyronine sodium, lomefloxacin, lymecycline, methylenecycline, methylprednisolone, metopimazine, metoprolol, minocycline, moxifloxacin, nizatidine, norfloxacin, ofloxacin, oxomemazine, oxytetracycline, pefloxacin, penicillamine, phosphorus, piperazine, pipotiazine, prednisolone, prednisone, proguanil, promethazine, propericiazine, propranolol, tranitidine, rosuvastatin, sulpiride, teriflunomide, tetracycline, thyroxines, vignecycline, tiratricol, triamcinolone, ulipristal.
Association not recommended: Raltegravir or bictegravir: Decreased absorption of these substances.
Drug Incompatibility: Due to the lack of studies on drug incompatibility, do not mix this drug with other drugs.
Store at temperatures below 30°C.
Shelf-life: 24 months from the date of manufacture.
A02AD01 - ordinary salt combinations ; Belongs to the class of combinations and complexes of aluminium, calcium and magnesium-containing antacids.
Đăng xuất
